Effect of family history of cancer on postoperative survival in patients with non-small cell lung cancer.

IF 4 2区医学 Q2 ONCOLOGY

Translational lung cancer research Pub Date : 2024-08-31 Epub Date: 2024-08-21 DOI:10.21037/tlcr-24-349

Jian Zhou, Quan Zheng, Yuchen Huang, Mengyuan Lyu, Tengyong Wang, Dongsheng Wu, Hu Liao

{"title":"Effect of family history of cancer on postoperative survival in patients with non-small cell lung cancer.","authors":"Jian Zhou, Quan Zheng, Yuchen Huang, Mengyuan Lyu, Tengyong Wang, Dongsheng Wu, Hu Liao","doi":"10.21037/tlcr-24-349","DOIUrl":null,"url":null,"abstract":"Background: Family history of cancer (FHC) has been reported to increase mortality of non-small cell lung cancer, mainly comprised of lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC). However, the impact of FHC on long-term survival remains controversial. This study aims to identify the impact of FHC on postoperative survival in LUAD and LUSC.Methods: Patients underwent lung resection for LUAD or LUSC in West China Hospital from 2009 to 2021 were enrolled. The 5-year overall survival (OS), lung cancer-specific survival (LCSS) and progression-free survival (PFS) were compared between the patients with and without FHC. Multivariable Cox regression was also performed.Results: A total of 6,253 patients were enrolled, including 5,685 LUAD and 568 LUSC. Altogether 18.9% (1,077/5,685) patients had FHC in LUAD, and 12.7% (72/568) patients had FHC in LUSC. In LUAD, the patients with FHC showed comparable survival compared with the patients without FHC regarding 5-year OS (87.9% vs. 86.5%, P=0.49), 5-year PFS (84.8% vs. 80.9%, P=0.06), and 5-year LCSS (89.2% vs. 88.0%, P=0.96). In LUSC, the patients with FHC had poorer survival compared with the patients without FHC according to 5-year OS (40.9% vs. 68.2%, P=0.007), 5-year PFS (42.3% vs. 66.2%, P=0.003), and 5-year LCSS (45.8% vs. 72.7%, P=0.003). Multivariate analyses indicated that FHC was an independent prognostic factor of OS, PFS, and LCSS in the patients with LUSC.Conclusions: FHC was associated with a poor survival after lung resection in LUSC not LUAD patients. More attention should be paid in postoperative monitoring and treatment in LUSC patients with FHC.","PeriodicalId":23271,"journal":{"name":"Translational lung cancer research","volume":null,"pages":null},"PeriodicalIF":4.0000,"publicationDate":"2024-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11384475/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational lung cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tlcr-24-349","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/21 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Family history of cancer (FHC) has been reported to increase mortality of non-small cell lung cancer, mainly comprised of lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC). However, the impact of FHC on long-term survival remains controversial. This study aims to identify the impact of FHC on postoperative survival in LUAD and LUSC.

Methods: Patients underwent lung resection for LUAD or LUSC in West China Hospital from 2009 to 2021 were enrolled. The 5-year overall survival (OS), lung cancer-specific survival (LCSS) and progression-free survival (PFS) were compared between the patients with and without FHC. Multivariable Cox regression was also performed.

Results: A total of 6,253 patients were enrolled, including 5,685 LUAD and 568 LUSC. Altogether 18.9% (1,077/5,685) patients had FHC in LUAD, and 12.7% (72/568) patients had FHC in LUSC. In LUAD, the patients with FHC showed comparable survival compared with the patients without FHC regarding 5-year OS (87.9% vs. 86.5%, P=0.49), 5-year PFS (84.8% vs. 80.9%, P=0.06), and 5-year LCSS (89.2% vs. 88.0%, P=0.96). In LUSC, the patients with FHC had poorer survival compared with the patients without FHC according to 5-year OS (40.9% vs. 68.2%, P=0.007), 5-year PFS (42.3% vs. 66.2%, P=0.003), and 5-year LCSS (45.8% vs. 72.7%, P=0.003). Multivariate analyses indicated that FHC was an independent prognostic factor of OS, PFS, and LCSS in the patients with LUSC.

Conclusions: FHC was associated with a poor survival after lung resection in LUSC not LUAD patients. More attention should be paid in postoperative monitoring and treatment in LUSC patients with FHC.

查看原文本刊更多论文

癌症家族史对非小细胞肺癌患者术后存活率的影响。

背景：据报道，癌症家族史（FHC）会增加非小细胞肺癌（主要包括肺腺癌（LUAD）和肺鳞癌（LUSC））的死亡率。然而，FHC 对长期生存的影响仍存在争议。本研究旨在确定 FHC 对 LUAD 和 LUSC 术后生存率的影响：方法：选取2009年至2021年在华西医院接受肺切除术的LUAD或LUSC患者作为研究对象。比较有FHC和无FHC患者的5年总生存期（OS）、肺癌特异性生存期（LCSS）和无进展生存期（PFS）。同时还进行了多变量考克斯回归：共有6253名患者入组，其中包括5685名LUAD患者和568名LUSC患者。18.9%（1,077/5,685）的 LUAD 患者患有 FHC，12.7%（72/568）的 LUSC 患者患有 FHC。在LUAD中，与无FHC的患者相比，有FHC的患者在5年OS（87.9% vs. 86.5%，P=0.49）、5年PFS（84.8% vs. 80.9%，P=0.06）和5年LCSS（89.2% vs. 88.0%，P=0.96）方面的生存率相当。在LUSC中，根据5年OS（40.9% vs. 68.2%，P=0.007）、5年PFS（42.3% vs. 66.2%，P=0.003）和5年LCSS（45.8% vs. 72.7%，P=0.003），与无FHC的患者相比，有FHC的患者生存率较低。多变量分析表明，FHC是LUSC患者OS、PFS和LCSS的独立预后因素：结论：FHC与LUSC而非LUAD患者肺切除术后的生存率有关。结论：FHC 与 LUSC 而非 LUAD 患者肺切除术后的不良生存率相关，因此应更加重视对 FHC LUSC 患者的术后监测和治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Translational lung cancer research Medicine-Oncology

CiteScore

7.20

自引率

2.50%

发文量

137

期刊介绍： Translational Lung Cancer Research(TLCR, Transl Lung Cancer Res, Print ISSN 2218-6751; Online ISSN 2226-4477) is an international, peer-reviewed, open-access journal, which was founded in March 2012. TLCR is indexed by PubMed/PubMed Central and the Chemical Abstracts Service (CAS) Databases. It is published quarterly the first year, and published bimonthly since February 2013. It provides practical up-to-date information on prevention, early detection, diagnosis, and treatment of lung cancer. Specific areas of its interest include, but not limited to, multimodality therapy, markers, imaging, tumor biology, pathology, chemoprevention, and technical advances related to lung cancer.